Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Martina Fahl"'
Autor:
Jerkeman, Mats, Kolstad, Arne, Hutchings, Martin, Pasanen, Annika, Meriranta, Leo, Niemann, Carsten Utoft, Jørgensen, Rasmus Rask Kragh, El-Galaly, Tarec Christoffer, Riise, Jon, Leppä, Sirpa, Christensen, Jacob Haaber, Sonnevi, Kristina, Pedersen, Lone Bredo, Wader, Karin Inger Martina Fahl, Glimelius, Ingrid
Externí odkaz:
https://hdl.handle.net/11250/3152771
Autor:
Jörg Schrader, Ansgar W. Lohse, Jakob R. Izbicki, Maximillian Bockhorn, Daniel Perez, Corinna Eggers, Martina Fahl, Bence Sipos, Jan Dieckhoff, Markus Möbs, Patricia Grabowski, Martin Anlauf, Felix R. Stahl, Susanne Burdak-Rothkamm, Gerrit Wolters-Eisfeld, Victoria Weissmann, Ludmilla Unrau, Yasmin Behrang, Daniel Benten
Neuroendocrine Phenotype and mutational status NT-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a145119b5799c888c609d56c132e3913
https://doi.org/10.1158/1541-7786.22516795.v1
https://doi.org/10.1158/1541-7786.22516795.v1
Data from Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model
Autor:
Jörg Schrader, Ansgar W. Lohse, Jakob R. Izbicki, Maximillian Bockhorn, Daniel Perez, Corinna Eggers, Martina Fahl, Bence Sipos, Jan Dieckhoff, Markus Möbs, Patricia Grabowski, Martin Anlauf, Felix R. Stahl, Susanne Burdak-Rothkamm, Gerrit Wolters-Eisfeld, Victoria Weissmann, Ludmilla Unrau, Yasmin Behrang, Daniel Benten
Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited. Development of new drugs requires suitable representative in vitro and in vivo model systems. So far, the unavailability of a human model with a well-differentiated phe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03c6d542614a5bfff10ae563162a6bfa
https://doi.org/10.1158/1541-7786.c.6541486
https://doi.org/10.1158/1541-7786.c.6541486
Autor:
Jörg Schrader, Ansgar W. Lohse, Jakob R. Izbicki, Maximillian Bockhorn, Daniel Perez, Corinna Eggers, Martina Fahl, Bence Sipos, Jan Dieckhoff, Markus Möbs, Patricia Grabowski, Martin Anlauf, Felix R. Stahl, Susanne Burdak-Rothkamm, Gerrit Wolters-Eisfeld, Victoria Weissmann, Ludmilla Unrau, Yasmin Behrang, Daniel Benten
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bdbd82b5c8c6d072de43793288c4626
https://doi.org/10.1158/1541-7786.22516777.v1
https://doi.org/10.1158/1541-7786.22516777.v1
Autor:
Fabrice Viol, Bence Sipos, Martina Fahl, Till S. Clauditz, Tania Amin, Malte Kriegs, Maike Nieser, Jakob R. Izbicki, Samuel Huber, Ansgar W. Lohse, Jörg Schrader
Publikováno v:
Cellular oncology (Dordrecht).
Purpose Gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) form a rare and remarkably heterogeneous group of tumors. Therefore, establishing personalized therapies is eminently challenging. To achieve progress in preclinical drug development,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::841bffdf3b6f28691c4c7dfc415897c0
https://pubmed.ncbi.nlm.nih.gov/36269546
https://pubmed.ncbi.nlm.nih.gov/36269546
Autor:
Tania Amin, Fabrice Viol, Jenny Krause, Martina Fahl, Corinna Eggers, Fayez Awwad, Benjamin Schmidt, Daniel Benten, Hendrik Ungefroren, Christoph Fraune, Till S. Clauditz, Guido Sauter, Jakob R. Izbicki, Ansgar W. Lohse, Samuel Huber, Jörg Schrader
Publikováno v:
Neuroendocrinology.
Introduction: Cancer-associated fibroblasts (CAF) have been identified as relevant contributors to cancer progression and drug resistance in many tumors. Although neuroendocrine tumors (NET) are often associated with a strong stromal reaction, no stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d50c2791a44cb6d6d6a17341b4b7ad3
https://pubmed.ncbi.nlm.nih.gov/36473454
https://pubmed.ncbi.nlm.nih.gov/36473454
Autor:
Corinna Eggers, Daniel Perez, Ludmilla Unrau, Jörg Schrader, Patricia Grabowski, Martin Anlauf, Jakob R. Izbicki, Markus Möbs, Bence Sipos, Gerrit Wolters-Eisfeld, Susanne Burdak-Rothkamm, Yasmin Behrang, Maximillian Bockhorn, Felix R. Stahl, Ansgar W. Lohse, Victoria Weissmann, Jan Dieckhoff, Martina Fahl, Daniel Benten
Publikováno v:
Molecular cancer research : MCR. 16(3)
Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited. Development of new drugs requires suitable representative in vitro and in vivo model systems. So far, the unavailability of a human model with a well-differentiated phe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58d8bfd7624de02f1ec21a2117f99c92
https://pubmed.ncbi.nlm.nih.gov/29330294
https://pubmed.ncbi.nlm.nih.gov/29330294